Abstract: Embodiments herein relate to cell encapsulation membranes, devices including the same, and related methods. In an embodiment, a cell encapsulation membrane is included. The cell encapsulation membrane can include a mesh substrate. The mesh substrate can include a first series of fibers extending in a first direction and a second series of fibers extending in a second direction, the first series of fibers intersecting with the second series of fibers, the mesh substrate defining a plurality of apertures disposed between adjacent fibers of the first series and the second series. The cell encapsulation membrane can further include a coating disposed on the mesh substrate, the coating partially occluding the plurality of apertures defined by the mesh substrate and forming pores. Other embodiments are also included herein.
Type:
Grant
Filed:
April 5, 2021
Date of Patent:
July 4, 2023
Assignee:
Boston Scientific Limited
Inventors:
Martin Lawrence Fawdry, Aiden Flanagan, Matthew McEvaddy, Garry Duffy, Eamonn J. Tuohy
Abstract: The present invention relates to new, oil-based suspension concentrates of agrochemical active compounds, a process for the preparation of these formulations and their use for the application of the active compounds contained.
Type:
Grant
Filed:
August 16, 2016
Date of Patent:
June 27, 2023
Assignee:
BAYER CROPSCIENCE AKTIENGESELLSCHAFT
Inventors:
Malcolm Faers, Oliver Gaertzen, Andreas Roechling, Arno Ratschinski
Abstract: Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of bacterial vaginosis (BV).
Type:
Grant
Filed:
May 31, 2021
Date of Patent:
June 27, 2023
Assignee:
LUPIN, INC.
Inventors:
Helen S. Pentikis, David Palling, Carol J. Braun
Abstract: The mixture of certain amine salts of glyphosate and 2,4-D allows the preparation of high-strength liquid compositions containing up to greater than 450 gae/L of total active ingredient loading if the pH is adjusted to about 6.0 to about 8.0. Compositions are particularly well-suited for application to crops that are resistant or tolerant to both glyphosate and 2,4-D.
Type:
Grant
Filed:
March 11, 2016
Date of Patent:
June 20, 2023
Assignee:
CORTEVA AGRISCIENCE LLC
Inventors:
Mei Li, Holger Tank, Lei Liu, Kuide Qin, Stephen L. Wilson, David G. Ouse
Abstract: A reagent composition for delivery nucleic acid therapeutics to cells is provided. The reagent includes ionizable lipid, structural lipid, and a stabilizing agent which improves the transfection efficiency of nucleic acids, and leaves transfected cells viable. The 5 transfection reagent is effective in plasmid and mRNA delivery, and in neurons and progenitor-like cells. It may be used for ex vivo cell therapy.
Type:
Grant
Filed:
April 15, 2019
Date of Patent:
June 20, 2023
Assignee:
Precision Nanosystems ULC
Inventors:
Anitha Thomas, Andrew William Brown, Rebecca Anne Grace De Souza, Tara L. Fernandez
Abstract: Described is an aqueous calcium gluconate solution formulated without calcium saccharate, which can be stored in a flexible plastic bag and can be terminally sterilized.
Abstract: Disclosed are methods, systems, media, apparatus, devices, and other implementations, including a method that includes determining blood flow characteristics at an ocular surface of an eye of a patient, determining characteristics of blood vessels at the ocular surface of the eye based on the determined blood flow characteristics, and deriving one or more ocular redness grading scales indicative of inflammation levels of the eye of the patient based on the determined characteristics of the blood vessels at the ocular surface of the eye.
Type:
Grant
Filed:
October 7, 2020
Date of Patent:
June 13, 2023
Assignee:
Tufts Medical Center, Inc.
Inventors:
Pedram Hamrah, William Warr Binotti, Ricardo Menon Nose
Abstract: Hot melt extrusion is disclosed as a process for forming vaginal drug delivery films. The methods involve extruding a composition comprising one or more active pharmaceutical ingredients and one or more polymer carriers at an elevated temperature through a die to thereby provide the film. Films prepared by hot melt extrusion are also described.
Type:
Grant
Filed:
June 28, 2018
Date of Patent:
June 13, 2023
Assignee:
UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Abstract: An antibiotic-eluting article for implantation into a mammalian subject, produced by an additive manufacturing process wherein a polymeric material is concurrently deposited with a selected antibiotic. The additive manufacturing process is a fused deposition modeling process. The antibiotic-eluting article may be temporary or permanent orthopaedic skeletal component, an orthopaedic articulating joint replacement component, and/or an external hard-shell casing for an implantable device. One or more bone-growth-promoting compositions may be concurrently deposited with the polymeric material. The implantable device may be a cardiac pacemaker, a spinal cord stimulator, a neurostimulation system, an intrathecal drug pump for delivery of medicants into the spinal fluid, and infusion pump for delivery of chemotherapeutics and or anti-spasmodics, an insulin pump, an osmotic pump, and a heparin pump.
Abstract: An aqueous oral care fluoride treatment composition, a method of providing fluoride to a patients tooth surface, and a method of reducing the incidence of dental caries, wherein the composition includes: 0.5 wt-% to 4.8 wt-% of a water-soluble cationic N-containing polymer; a pharmaceutically acceptable buffer; 1.0 wt-% to 2.5 wt-% of sodium fluoride; and at least 60 wt-% water; wherein the weight percentages are based on the total weight of the aqueous composition.
Type:
Grant
Filed:
August 22, 2018
Date of Patent:
June 6, 2023
Assignee:
3M INNOVATIVE PROPERTIES COMPANY
Inventors:
Yizhong Wang, Tiffany T. Ton, Carola A. Carrera Vidal, Joel D. Oxman, Jennifer J. Post, Paul R. Klaiber
Abstract: The present invention provides a new formulation which includes Elsholtzia ciliata Extract. Experiments have shown that ECE decreases the rate of depolarization of upstroke of myocardial action potential, slows the propagation of electrical excitation and distributes the ECG QRS range, i.e. treats the heart as a first-class anti-arrhythmic drug. Due to its herbal origin, the ECE can be well tolerated and widely used as a safe drug for eliminating cardiac arrhythmias.
Type:
Grant
Filed:
April 6, 2018
Date of Patent:
May 23, 2023
Assignee:
LIETUVOS SVEIKATOS MOKSLU UNIVERSITETAS
Inventors:
Jurga Bernatoniene, Lauryna Pudziuvelyte, Jonas Jurevicius, Regina Macianskiene, Sandrita Simonyte
Abstract: The present application provides a semi-permeable hydrogel composition comprising an alginate matrix that is covalently crosslinked in its periphery to a multi-armed water soluble polymer, along with related methods and uses thereof.
Type:
Grant
Filed:
March 21, 2017
Date of Patent:
May 23, 2023
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
Venkata R. Garigapati, Tetsuo Hoshino, Amit Garle
Abstract: A melt processed viral nanoparticle construct for delivery of virus or virus-like particles to a site of interest includes a degradable polymer matrix and a plurality of virus or virus-like particles encapsulated within the degradable polymer matrix. The nanoparticle construct upon administration to the site of interest providing a sustained release of the virus or virus-like particles and/or nanoparticles upon degradation of the polymer matrix.
Abstract: A cavitation seed for drug delivery, and a drug delivery method using the same are disclosed. The cavitation seed according to the present invention comprises: a shell which forms the outer surface thereof to maintain the outer shape thereof within a fluid; and a core which is located inside the shell to determine buoyancy of the cavitation seed within the fluid. The cavitation seed can improve an effect of delivering a drug into a body since cavitation is induced by ultrasound at a position close to the epidermis. In addition, the cavitation seed can be applied in the delivery of various drugs as well as skin cosmetics, such as skin tone lightening agents, depilatories, hair restorers and skin fillers, skin analgesics, local anesthetics, agents for genetic diseases such as psoriasis, and agents for treatment of skin disease such as skin cancer.
Type:
Grant
Filed:
April 8, 2021
Date of Patent:
May 23, 2023
Assignee:
Pacific System Co., Ltd.
Inventors:
Jong Woo Seo, Jong Bum Seo, Gill Soo Song
Abstract: Disclosed are compositions comprised of Oxidized Cellulose (OC), such as oxidized regenerated cellulose (ORC), and an antibiotic comprised of minocycline, methods of preparation thereof and uses thereof.
Type:
Grant
Filed:
April 12, 2021
Date of Patent:
May 23, 2023
Assignees:
OMRIX BIOPHARMACEUTICALS LTD., ETHICON, INC.
Inventors:
Eve Montia, Dwayne Looney, Theresa Scheuble, Ronen Eavri, Roi Mashiach
Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine.
Abstract: The present invention relates to prepare pharmaceutical compositions comprising pimavanserin or a pharmaceutically acceptable salt thereof, processes for manufacturing said pharmaceutical compositions comprising pimavanserin or a pharmaceutically acceptable salt thereof. Also pharmaceutical compositions comprising pimavanserin or a pharmaceutically acceptable salt thereof for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Abstract: Residence devices for long term delivery of therapeutic compounds and/or for sensing one or more relevant parameters in vivo are disclosed. In one embodiment, a residence device may include a plurality of links interconnected by a corresponding plurality of flexible hinges to permit the residence device to be deformed into a contracted configuration and subsequently permitted to return to an expanded configuration once positioned in a desired location, such as the stomach, of a subject. In some instances, at least a portion of the interconnected links may include a first link segment, a second link segment, and a coupling that selectively connects the first link segment to the second link segment. The coupling may be configured to weaken or decouple a connection between the first link segment and the second link segment when exposed to a temperature greater than a threshold temperature to selectively weaken and/or disassemble the residence device.
Type:
Grant
Filed:
November 15, 2019
Date of Patent:
May 16, 2023
Assignees:
Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
Inventors:
Robert S. Langer, Carlo Giovanni Traverso, Sahab I Babaee, Simo Pajovic, Jiuyun | Shi
Abstract: Disclosed is a dry powder oral formulation that includes an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation. Also disclosed are an excipient composition in absence of an API and methods of making and using the formulations and compositions. Also disclosed is a chewable, swallowable, and/or orally disintegrating tablet comprising an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation.
Abstract: An autologous bone graft substitute composition for inducing new bone formation, promoting bone growth and treating bone defects. The composition includes autologous blood; one or more analogs of an osteogenic bone morphogenetic protein selected from BMP-6, BMP-2, BMP-7, BMP-4, BMP-5, BMP-8, BMP-9, BMP-12, and BMP-13, and combinations thereof in a range of from 2 to 1000 ?g per ml of autologous blood; and hydroxyapatite, tri-calcium phosphate, or a mixture thereof as a compression resistant matrix, the compression resistant matrix being provided in the form of particles having a particle size in a range of from above 74 to 8000 ?m. Preferably, a ratio between the compression resistant matrix and the autologous blood coagulum is from 50 to 500 mg of the compression resistant matrix per mL of the autologous blood coagulum.